التفاصيل البيبلوغرافية
| العنوان: |
Impact of SARS-CoV-2 vaccination and booster on COVID-19 symptom severity over time in the COVID-OUT trial |
| المؤلفون: |
Boulware, David R, Murray, Thomas A, Proper, Jennifer L, Tignanelli, Christopher J, Buse, John B, Liebovitz, David M, Nicklas, Jacinda M, Cohen, Kenneth, Puskarich, Michael A, Belani, Hrishikesh K, Siegel, Lianne K, Klatt, Nichole R, Odde, David J, Karger, Amy B, Ingraham, Nicholas E, Hartman, Katrina M, Rao, Via, Hagen, Aubrey A, Patel, Barkha, Fenno, Sarah L, Avula, Nandini, Reddy, Neha V, Erickson, Spencer M, Lindberg, Sarah, Fricton, Regina, Lee, Samuel, Zaman, Adnin, Saveraid, Hanna G, Tordsen, Walker J, Pullen, Matthew F, Sherwood, Nancy E, Huling, Jared D, Bramante, Carolyn T |
| المصدر: |
Clin Infect Dis |
| بيانات النشر: |
Oxford University Press |
| سنة النشر: |
2022 |
| مصطلحات موضوعية: |
Major Article, demo, psy |
| الوصف: |
BACKGROUND: SARS-CoV-2 vaccination has decreasing protection from acquiring any infection with emergence of new variants; however, vaccination continues to protect against progression to severe COVID-19. The impact of vaccination status on symptoms over time is less clear. METHODS: Within a randomized trial on early outpatient COVID-19 therapy testing metformin, ivermectin, and/or fluvoxamine, participants recorded symptoms daily for 14 days. Participants were given a paper symptom diary allowing them to circle the severity of 14 symptoms as none (0), mild (1), moderate (2), or severe (3). This is a secondary analysis of clinical trial data on symptom severity over time using generalized estimating equations comparing those unvaccinated, SARS-CoV-2 vaccinated with primary vaccine series only, or vaccine-boosted. RESULTS: The parent clinical trial prospectively enrolled 1323 participants, of whom 1062 (80%) prospectively recorded some daily symptom data. Of these, 480 (45%) were unvaccinated, 530 (50%) were vaccinated with primary series only, and 52 (5%) vaccine-boosted. Overall symptom severity was least for the vaccine-boosted group and most severe for unvaccinated at baseline and over the 14 days (P < 0.001). Individual symptoms were least severe in the vaccine-boosted group including: cough, chills, fever, nausea, fatigue, myalgia, headache, and diarrhea, as well as smell and taste abnormalities. Results were consistent over delta and omicron variant time periods. CONCLUSIONS: SARS-CoV-2 vaccine-boosted participants had the least severe symptoms during COVID-19 which abated the quickest over time. |
| نوع الوثيقة: |
text |
| اللغة: |
English |
| العلاقة: |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494422Test/ |
| الإتاحة: |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494422Test/ |
| حقوق: |
undefined |
| رقم الانضمام: |
edsbas.E80799D7 |
| قاعدة البيانات: |
BASE |
